These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 27754705)

  • 1. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
    Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
    J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice.
    Badia-Ramentol J; Gimeno-Valiente F; Duréndez E; Martínez-Ciarpaglini C; Linares J; Iglesias M; Cervantes A; Calon A; Tarazona N
    Cancer Treat Rev; 2023 Dec; 121():102643. PubMed ID: 37871463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Caudal-Type Homologous Transcription Factor-2 (CDX2) in Duodenal Carcinoma and its Relationship with Prognosis.
    Pan J; Jiao X; Yang Z; Li J; Chen Y; Chu X
    Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38518166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brush border myosin Ia has tumor suppressor activity in the intestine.
    Mazzolini R; Dopeso H; Mateo-Lozano S; Chang W; Rodrigues P; Bazzocco S; Alazzouzi H; Landolfi S; Hernández-Losa J; Andretta E; Alhopuro P; Espín E; Armengol M; Tabernero J; Ramón y Cajal S; Kloor M; Gebert J; Mariadason JM; Schwartz S; Aaltonen LA; Mooseker MS; Arango D
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1530-5. PubMed ID: 22307608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary adenocarcinoma of colon: A clinicopathological study with the prevalence and correlation of CDX2 biomarker expression - A tertiary care center experience.
    Issac R; Masih D; Ranjan M; Pulimood AB
    Indian J Cancer; 2023 Apr; ():. PubMed ID: 38155448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDX2 inducible microRNAs sustain colon cancer by targeting multiple DNA damage response pathway factors.
    Priya S; Kaur E; Kulshrestha S; Pandit A; Gross I; Kumar N; Agarwal H; Khan A; Shyam R; Bhagat P; Prabhu JS; Nagarajan P; Deo SVS; Bajaj A; Freund JN; Mukhopadhyay A; Sengupta S
    J Cell Sci; 2021 Aug; 134(15):. PubMed ID: 34369561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer.
    Fernandez-De-Los-Reyes I; Gomez-Dorronsoro M; Monreal-Santesteban I; Fernandez-Fernandez A; Fraga M; Azcue P; Alonso L; Fernandez-Marlasca B; Suarez J; Cordoba-Iturriagagoitia A; Guerrero-Setas D
    Clin Epigenetics; 2023 Dec; 15(1):193. PubMed ID: 38093305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.
    Draht MXG; Goudkade D; Koch A; Grabsch HI; Weijenberg MP; van Engeland M; Melotte V; Smits KM
    Clin Epigenetics; 2018; 10():35. PubMed ID: 29564023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.
    Vedeld HM; Goel A; Lind GE
    Semin Cancer Biol; 2018 Aug; 51():36-49. PubMed ID: 29253542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.
    Olsen J; Espersen ML; Jess P; Kirkeby LT; Troelsen JT
    Surg Oncol; 2014 Sep; 23(3):167-76. PubMed ID: 25126956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal Cancer.
    Jiang G; Luo C; Sun M; Zhao Z; Li W; Chen K; Fan T
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):710-714. PubMed ID: 27754705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
    Graule J; Uth K; Fischer E; Centeno I; Galván JA; Eichmann M; Rau TT; Langer R; Dawson H; Nitsche U; Traeger P; Berger MD; Schnüriger B; Hädrich M; Studer P; Inderbitzin D; Lugli A; Tschan MP; Zlobec I
    Clin Epigenetics; 2018 Sep; 10(1):120. PubMed ID: 30257705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter methylation downregulates CDX2 expression in colorectal carcinomas.
    Kawai H; Tomii K; Toyooka S; Yano M; Murakami M; Tsukuda K; Shimizu N
    Oncol Rep; 2005 Mar; 13(3):547-51. PubMed ID: 15706431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.